Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

IMW 2019 | GMMG-HD4 and MM5: bortezomib vs. lenalidomide for myeloma maintenance

Elias Mai • 15 Sep 2019
IMW 2019
Multiple Myeloma Bortezomib Lenalidomide
GMMG-MM5 HOVON-65/GMMG-HD4

Elias Mai, MD, from the University Hospital Heidelberg, Heidelberg, Germany, talks about the GMMG-HD4 (NCT03617731) and MM5 (EudraCT no. 2010-019173-16) trials of bortezomib versus lenalidomide maintenance therapy for myeloma. This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Elias Mai

HRQoL in patients with transplant-eligible newly diagnosed myeloma treated with Isa-RVd vs Rvd alone
2:00
HRQoL in patients with transplant-eligible newly diagnosed myeloma treated with Isa-RVd vs Rvd alone
Elias Mai • 6 Dec 2025
Isa-RVd induction therapy in patients with newly diagnosed multiple myeloma: the GMMG-HD7 trial
4:22
Isa-RVd induction therapy in patients with newly diagnosed multiple myeloma: the GMMG-HD7 trial
Elias Mai • 9 Dec 2024
Predicting and preventing early relapse in patients with newly diagnosed multiple myeloma
2:48
Predicting and preventing early relapse in patients with newly diagnosed multiple myeloma
Elias Mai • 9 Dec 2024
Advantages and applications of mass spectrometry in multiple myeloma
1:03
Advantages and applications of mass spectrometry in multiple myeloma
Elias Mai • 25 Apr 2023

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Elias Mai • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Elias Mai • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Elias Mai • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Elias Mai • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals